Thelansis

  Peripheral T-cell lymphoma (PTCL) is a group of rare and usually aggressive (fast-growing) Non-Hodgkin’s Lymphomas (NHL) that develops from mature T-cells. It originates from mature-stage white blood cells called T-cells and natural killer (NK) cells. A subtype of Non-Hodgkin’s Lymphoma (NHL) specifically affects T-cells and results when T-cells develop and grow abnormally. Patients with PTCL have a poor prognosis, with treatment characterized by multiple relapses and initial refractory disease. If stem cell transplantation is considered the next step in therapy, patients with relapsed disease are usually treated with combined chemotherapy (ICE) (ifosfamide, carboplatin, and etoposide). However, some regimens or transplants may not suit everyone due to their high toxicity levels. Single-agent treatments that are less toxic are also available and may induce long-term remission in such patients. Brentuximab vedotin (Adcetris), Belinostat (Beleodaq), pralatrexate (Folotyn), and romi...